| Literature DB >> 32467737 |
Mohammad Reza Abbaszadegan1, Majid Mojarrad2, Meysam Moghbeli2.
Abstract
BACKGROUND: Gastric cancer (GC) is one of the most common cancers in the world with a high ratio of mortality. Regarding the late diagnosis, there is a high ratio of distant metastasis among GC cases. Despite the recent progresses in therapeutic modalities, there is not still an efficient therapeutic method to increase survival rate of metastatic GC cases. MAIN BODY: Apart from the various intracellular signaling pathways which are involved in tumor cell migration and metastasis, the local microenvironment is also a critical regulator of tumor cell migration. Indeed, the intracellular signaling pathways also exert their final metastatic roles through regulation of extra cellular matrix (ECM). Therefore, it is required to assess the role of extra cellular components in biology of GC.Entities:
Keywords: Extra cellular matrix; Gastric Cancer; Metastasis; Microenvironment
Year: 2020 PMID: 32467737 PMCID: PMC7227337 DOI: 10.1186/s41021-020-00157-z
Source DB: PubMed Journal: Genes Environ ISSN: 1880-7046
All of the ECM related factors involved in gastric cancer progression and metastasis
| Gene | Results | Country | population | Year | Reference |
|---|---|---|---|---|---|
| MMP9 | Polymorphism was correlated with invasive phenotype | Japan | 177 patients 224 controls | 2005 | Matsumura [ |
| MMP9 | MMP9 expression was correlated with stage, depth of tumor invasion, and lymph node involvement | Poland | 54 patients | 2009 | Mroczko [ |
| MMP9 | increased levels of expression in advanced stage tumors | Serbia | 40 patients 11 controls | 2009 | Dragutinovic [ |
| MMP1 | Polymorphism was correlated with poorly differentiation | Japan | 215 patients 166 controls | 2004 | Matsumura [ |
| MMP1 | Polymorphism was correlated with GC risk | China | 422 patients 428 controls | 2014 | Dedong [ |
| MMP2 | MMP2 expression was correlated with poor survival, stage, and diffuse type | Finland | 315 patients | 2006 | Mrena [ |
| MMP14 | High levels of serum MMP14 was correlated with poor survival | Finland | 240 patients | 2018 | Kasurinen [ |
| MMP7 and LAMC2 | MMP7 and LAMC2 expressions were correlated with tumor aggressiveness | Japan | 790 patients | 2014 | Sentani [ |
| ADAMTS8, ADAMTS18, and ADAMTS1 | Expressions were correlated with stage | Turkey | 25 patients | 2017 | Kilic [ |
| TIMP1 | TIMP1 expression was correlated with advanced stages, increased depth of invasion, and metastatic lymph nodes | Poland | 54 patients | 2009 | Mroczko [ |
| MMP2, MMP24, and MMP25 | MMP2, MMP24, and MMP25 increased expression | Mexico | 17 patients 22 controls | 2014 | De la pena [ |
| LOX | Over expression was correlated with local tumor relapse | China | 184 patients | 2018 | Peng [ |
| LOXL4 | Over expression was correlated with tumor size, depth of invasion, stage, and survival | China | 379 patients | 2015 | Li [ |
| PLOD2 | Expression was correlated with peritoneal metastasis | Japan | 179 patients | 2018 | Kiyozumi [ |
| TFPI2 | Hyper methylation | China | 114 patients | 2017 | Hu [ |
| ETS1 | over expression induced mucosal into the sub mucosal tumor invasion | Japan | 110 patients | 1996 | Nakayama [ |
| BSG | Expression was correlated with tumor size and lymph node metastasis | Japan | 234 tumors 85 normal | 2006 | Zheng [ |
| MMRN2, EMILIN1, and EMILIN2 | High expression of MMRN2 in normal gastric mucosa along blood vessels, while the EMILIN2 and EMILIN1 expressions were limited to the lamina propria. | Italy | 51 patients | 2018 | Andreuzzi [ |
| HPSE | Polymorphism was correlated with survival | China | 155 patients 204 controls | 2010 | Yue [ |
| CTHRC1 | Expression was correlated with depth of invasion | China | 116 patients | 2012 | Wang [ |
| CTHRC1 | Expression was associated with tumor stage, differentiation, survival, and prognosis, depth of invasion, lymph node involvement, and tumor size. | China | 166 tumors 30 normal | 2014 | Gu [ |
| ECM1 | Expression was correlated with tumor relapse, poor survival, and advanced stages. | China | 241 patients | 2018 | Gan [ |
| ECM1 | Expression was correlated with tumor depth of invasion and stage. | China | 77 patients | 2014 | Wu [ |
| PCDH8 | Was correlated with poor prognosis. | China | 144 patients | 2018 | Lin [ |
| CLDN4 | Expression was correlated with depth of invasion and lymph node involvement | Taiwan | 189 patients | 2010 | Hwang [ |
| LLGL1 | Was correlated with distant metastasis. | Germany | 56 patients | 2019 | Desuki [ |
| FN1 | increased serum levels | Turkey | 63 patients 30 controls | 2016 | Tas [ |
| FNDC1 | Expression was correlated with sex, survival, and stage. | China | 90 patients | 2018 | Ren [ |
| ANOS1 | Expression was correlated with stage and prognosis. | Japan | 237 patients | 2016 | Kanda [ |
| ITGA4 | Methylation | Korea | 46 patients | 2004 | Park [ |
| ICAM1 (CD54) | Expressions were correlated with stage and lymph node involvement. | China | 84 patients | 2014 | Dong [ |
| CFL1 | Over expression | China | 33 patients | 2017 | Wang [ |
| HMMR (CD168) | Inverse correlation with lymph node involvement. | Japan | 196 patients | 2011 | Ishigami [ |
| MFAP2 | Expression was correlated with depth of invasion, lymph node involvement, tumor stage, and poor overall survival | China | 168 patients | 2018 | Wang [ |
| SPON2 | Expression was correlated with grade of tumor differentiation, depth of invasion, lymph node involvement, and advanced stages. | China | 174 patients | 2017 | Jin [ |
| SPARC | Was correlated with serosal invasion and poor survival. | Japan | 227 patients | 2013 | Sato [ |
| SERPINE1 AND SPARC | Expressions were correlated with poor survival. | China | 293 tumors 196 normal | 2018 | Liao [ |
| SPARCL1 | Expression was correlated with prognosis, survival, size, and grade. | China | 1072 patients | 2012 | Li [ |
| FGFR2 AND THBS1 | Over expressions | China | 53 patients | 2017 | Huang [ |
| LTBP2 | Expression was correlated with depth of invasion, stage, lymph node involvement, poor survival. | China | 174 patients | 2018 | Wang [ |
| POSTN | Inverse correlation between expression and stage. | China | 25 tumors 8 normal | 2014 | LV [ |
| VCAN | Expression was correlated with poor prognosis. | China | 101 patients | 2015 | Shen [ |
| ASPN | Over expression. | China | 46 patients | 2015 | Ding [ |
| LUM | Up regulation in gastric CAFs was correlated with advanced stage, poor survival, depth of invasion, and lymph node involvement. | China | 117 patients | 2017 | Wang [ |
| MUC2 | Was correlated with grade. | Egypt | 28 patients | 2011 | Khattab [ |
ECM related genes studied in GC patients
| Official symbol | Official full name | Gene ID | URL |
|---|---|---|---|
| ADAMTS1 | ADAM metallopeptidase with thrombospondin type 1 motif 1 | 9510 | |
| ADAMTS18 | ADAM metallopeptidase with thrombospondin type 1 motif 18 | 170,692 | |
| ADAMTS8 | ADAM metallopeptidase with thrombospondin type 1 motif 8 | 11,095 | |
| ANOS1 | Anosmin 1 | 3730 | |
| ASPN | Asporin | 54,829 | |
| BSG | Basigin (Ok blood group) (EMMPRIN) | 682 | |
| CFL1 | Cofilin 1 | 1072 | |
| CLDN4 | Claudin 4 | 1364 | |
| CTHRC1 | Collagen triple helix repeat containing 1 | 115,908 | |
| CXCR1 | C-X-C motif chemokine receptor 1 | 3577 | |
| CXCR2 | C-X-C motif chemokine receptor 2 | 3579 | |
| ECM1 | Extracellular matrix protein 1 | 1893 | |
| EGFR | Epidermal growth factor receptor | 1956 | |
| EMILIN1 | Elastin microfibril interfacer 1 | 11,117 | |
| EMILIN2 | Elastin microfibril interfacer 2 | 84,034 | |
| ETS1 | ETS proto-oncogene 1, transcription factor | 2113 | |
| FGF7 | Fibroblast growth factor 7 | 2252 | |
| FGFR2 | Fibroblast growth factor receptor 2 | 2263 | |
| FN1 | Fibronectin 1 | 2335 | |
| FNDC1 | Fibronectin type III domain containing 1 | 84,624 | |
| FOXC2 | Forkhead box C2 | 2303 | |
| HMMR | Hyaluronan mediated motility receptor (CD168) | 3161 | |
| HPSE | Heparanase | 10,855 | |
| ICAM1 | Intercellular adhesion molecule 1 (CD54) | 3383 | |
| ITGA4 | Integrin subunit alpha 4 | 3676 | |
| LAMC2 | Laminin subunit gamma 2 | 3918 | |
| LGALS1 | Galectin 1 | 3956 | |
| LLGL1 | LLGL scribble cell polarity complex component 1 | 3996 | |
| LOX | Lysyl oxidase | 4015 | |
| LOXL4 | Lysyl oxidase like 4 | 84,171 | |
| LTBP2 | Latent transforming growth factor beta binding protein 2 | 4053 | |
| LUM | Lumican | 4060 | |
| MFAP2 | Microfibril associated protein 2 | 4237 | |
| MMP1 | Matrix metallopeptidase 1 | 4312 | |
| MMP14 | Matrix metallopeptidase 14 | 4323 | |
| MMP2 | Matrix metallopeptidase 2 | 4313 | |
| MMP24 | Matrix metallopeptidase 24 | 10,893 | |
| MMP25 | Matrix metallopeptidase 25 | 64,386 | |
| MMP7 | Matirix metallopeptidase 7 | 4316 | |
| MMP9 | Matrix metallopeptidase 9 | 4318 | |
| MMRN2 | Multimerin 2 | 79,812 | |
| MUC2 | Mucin 2, oligomeric mucus/gel-forming | 4583 | |
| MUC6 | Mucin 6, oligomeric mucus/gel-forming | 4588 | |
| NODAL | Nodal growth differentiation factor | 4838 | |
| PCDH8 | Protocadherin 8 | 5100 | |
| PLOD2 | Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 | 5352 | |
| POSTN | Periostin | 10,631 | |
| SERPINE1 | Serpin family E member 1 | 5054 | |
| SPARC | Secreted protein acidic and cysteine rich | 6678 | |
| SPARCL1 | SPARC like 1 | 8404 | |
| SPON2 | Spondin 2 | 10,417 | |
| TFPI2 | Tissue factor pathway inhibitor 2 | 7980 | |
| THBS1 | Thrombospondin 1 | 7057 | |
| TIMP1 | TIMP metallopeptidase inhibitor 1 | 7076 | |
| TIMP3 | TIMP metallopeptidase inhibitor 3 | 7078 | |
| VCAN | Versican | 1462 |